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Abstract: Activation of the calcium-sensing receptor (CaSR) by ischemia/reperfusion (I/R) favours apoptosis in car-
diomyocytes, hepatocytes and neurons. Its role in renal I/R is unknown. We investigated the impact of pharmacologi-
cal preactivation of the CaSR on kidney structure and function in a murine model of bilateral renal 30-min ischemia 
and 48-hour reperfusion, and in a 6-year cohort of kidney transplant recipients (KTR). C57BL/6J mice were admin-
istered daily with CaSR agonist, R-568, or with vehicle for 48 hours. Evaluation of serum urea and creatinine levels, 
renal histology and urine metabolome by nuclear magnetic resonance showed that R-568 was not nephrotoxic per 
se. Following I/R, serum urea and creatinine levels increased higher in R-568-treated animals than in controls. 
Jablonski’s score was significantly greater in R-568-treated kidneys, which showed a higher rate of cell prolifera-
tion and apoptosis in comparison to controls. Next, we retrospectively identified 36 patients (10.7% of our cohort) 
who were treated by CaSR agonist, cinacalcet, at the time of kidney transplantation (KTx). After matching these to 
61 KTR upon type of donor, cold ischemic time, residual diuresis, and donor age, we observed that delayed graft 
function, i.e. need for dialysis in the first week after KTx, occurred in 42 and 23% of cinacalcet-treated and control 
groups, respectively (p≤0.05). These data suggest that pharmacological preactivation of the CaSR before renal I/R 
exacerbates kidney injury.
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Introduction
The Ca2+-sensing receptor (CaSR) belongs to 
family C of the G-protein-coupled receptor 
(GPCR) superfamily, and is ubiquitously exp- 
ressed [1, 2]. Its principal physiological ligand 
is the ion Ca2+. By sensing the variations of 
extracellular Ca2+ ([Ca2+]e) concentration, the 
CaSR plays a critical role in Ca2+ homeostasis. 
It notably controls parathormone (PTH) secre-
tion by the parathyroid glands and modulates 
Ca2+ fluxes in kidneys, intestine and bones 
[3-5]. The importance of the CaSR in Ca2+ 
homeostasis is supported by the chronic hyper- 
or hypocalcemia observed in patients harbor-
ing loss- or gain-of-function mutations, respec-
tively, in the CASR gene [6]. In addition, the 
EC50 value for Ca2+ binding to the CaSR can be 
significantly modified by several physiological 
parameters, including ionic strength, extracel-
lular pH, L-aromatic amino acids and poly-
amines, or by drugs, like the calcimimetic com-
pounds cinacalcet and R-568 [4]. Hence, 
cinacalcet is used in clinical routine to treat 
patients with primary hyperparathyroidism or 
with secondary hyperparathyroidism caused by 
chronic kidney disease (CKD), including individ-
uals registered on kidney transplantation (KTx) 
waiting list [7, 8]. 
The CaSR has been identified in numerous tis-
sues and cells that are not directly involved in 
Ca2+ homeostasis, in which its role remains 
unclear [9, 10]. In epithelia, the CaSR particu-
larly regulates cell proliferation, survival and 
Ca2+-induced polarization and differentiation 
[11-14]. Moreover, the CaSR has been implicat-
ed ex vivo and in vivo in the ischemia/reperfu-
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sion (I/R) cascade in cardiomyocytes [15, 16] 
and neurons [17], as well as in hepatocytes 
[18]. The occurrence of I/R typically involves 
the reduction or interruption of organ perfusion 
with a subsequent reflow. Such I/R event in- 
duces significant cell metabolism modifications 
[19], including increased expression of the 
CaSR, intracellular Ca2+ overload and activation 
of the mitochondrial and mitogen-activated 
protein kinase apoptotic pathways [15-18].
Transient I/R is the primary cause of acute 
kidney injury (AKI), a common situation curren- 
tly defined as a rapid fall of glomerular filtration 
rate (GFR) and/or a decline in urine output [20, 
21]. One of the paradigms of renal I/R is KTx. 
Indeed, graft procurement and storage neces-
sarily require the temporary interruption of 
renal blood flow, with subsequent reperfusion 
after transplantation. Such unavoidable I/R 
events contribute to delay graft recovery post 
KTx [22]. The role of the CaSR in kidney I/R has 
not been studied thus far. In order to transla-
tionally investigate the impact of CaSR activa-
tion before renal I/R on kidney structure and 
function, we first took advantage of a conven-
tional mouse model of bilateral clamping of 
renal pedicles. Next, we retrospectively studied 
a prospective cohort of kidney transplant recip-
ients (KTR) to test whether the use of cinacal-
cet (Sensipar®/Mimpara®) at the time of KTx 
influences early graft recovery.
Materials and methods
Acute renal ischemia in mice
All animal protocols were approved by the 
Ethics Committee for Animal Care and Use at 
the University of Liege School of Medicine (pro-
tocol number #1335). Ten-week-old male 
C57BL/6 mice weighing ~20 g were treated 
with i.p. injections of CaSR agonist, R-568 
(AMGEN), at 250 µg/d [23] or with a similar vo- 
lume of DMSO for 2 days before surgery. 
Animals were then anesthetized with pentobar-
bital (60 mg/kg, Ceva®) by i.p. injection and, 
using aseptic techniques, subjected to a lapa-
rotomy with bilateral renal pedicle clamping 
(“ischemia”) for 30 min. Ischemia was con-
firmed by color change observed in kidneys fol-
lowing clamping. Supportive fluids were given 
throughout the operative period, and hypother-
mia was prevented by use of an isothermal 
heating pad and warming lights. Following sur-
gery, animals were kept in light- and tempera-
ture-controlled conditions for 48 hours, with a 
twice-daily clinical evaluation of scar and gen-
eral health status. At 24 h post surgery, mice 
were placed in metabolic cages for 24 hours 
with ad libitum access to food and drinking 
water. Urine was collected on 2%-Na+ azide 
solution (Sigma®) with one drop of mineral oil 
(Sigma®) to prevent bacterial proliferation and 
evaporation, respectively. Urine metabolome 
was analyzed using 1H-NMR (see infra). Blood 
was obtained by vena cava puncture at the 
time of sacrifice. Serum levels of Ca2+, urea and 
creatinine were measured on a COBAS 6000 
C501 device (Roche-Hitachi®). At 48h post-sur-
gery, the animals were once again anesthetized 
and subjected to a laparotomy. Kidneys were 
collected, fixed in 4% paraformaldehyde (Boe- 
hringer Ingelheim, Heidelberg, Germany) in 0.1 
mol/L phosphate buffer, pH 7.4, prior to embed-
ding in paraffin, and further subjected to histo-
logical analyses [24]. 
Immunostaining
Six-µm sections were incubated for 30 minutes 
with 0.3% hydrogen peroxide to block endoge-
nous peroxidase. Antigen retrieval was per-
formed by incubating sections in 0.01 mol/L 
citrate buffer, pH 6.1, for 11 minutes, in an 
autoclave heated at 121°C, before cooling 
down for 20 min, and rinsing. Following incuba-
tion with 10% normal serum for 30 minutes, 
sections were incubated for 45 minutes with 
the primary antibodies diluted in phosphate-
buffered saline (PBS) containing 2% bovine 
serum albumin (BSA). After washing, sections 
were successively incubated with biotinylated 
secondary anti-immunoglobulin G antibodies 
(Dako®), avidin-biotin peroxidase (Merck®), and 
3,3-diaminobenzidine (DAB, Dako®). The speci-
ficity of immunostaining was tested by incuba-
tion (i) in absence of primary antiserum, or (ii) 
with control IgG (Vector Lab®). The use of 
ApopTag kit S7101 followed the manufacturer’s 
recommendations (Millipore®). Following immu-
nostaining, kidney sections were scanned 
using the NanoZoomer 2.0 HT (Hamamatsu®). 
The regions of interest were first distinguished 
(Supplementary Figure 1). The cortex is located 
between the capsula and the cortico-medullary 
junction (CMJ). CMJ is distinguishable from the 
cortex upon the absence of glomeruli, the pres-
ence of large venous spaces, and the shape of 
S3 straight PT. CMJ was further isolated from 
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the medulla according to the longitudinal vs. 
transversal orientation of the tubules. Next, 
immuno-reactive cells were systematically 
identified in each kidney section and counted 
using both direct visual method and www.cyto-
mine.be software (Supplementary Figure 1) 
[25]. Following a hybrid human-computer 
approach, tens of positive and negative cell 
examples were manually annotated. Then, a 
tree-based machine learning algorithm was 
used to build a positive pixel segmentation 
model further combined with connected-com-
ponent analysis and filtering operations based 
on size and circularity criteria. Automatic posi-
tive cell detections were proofread by experts. 
The number of positive cells and area statistics 
were then computed for each region of interest 
for each image. In addition to immunostaining 
experiments, routine colorations, i.e. Hema- 
toxylin-Eosine (HE) and periodic acid-Shiff, were 
classically performed. Sections were viewed 
under a Leica DM 1000 LED coupled to a Leica 
MC170 digital camera (Leica®). The severity of 
I/R-associated AKI was graded according to 
Jablonski’s score [26] by a pathologist special-
ized in renal pathology, unaware of animal 
groups. 
1H-NMR metabolomics
Urine samples (150 μl) were supplemented 
with 450 μl of deuterated phosphate buffer 
(DPB, pH 7.4), 100 μl of a 5 mM solution of 
maleic acid and 10 μl of a 10 mg/ml trimethyl-
silyl-3-propionic acid-d4 D2O (TMSP) solution. 
1H-NMR spectra were acquired using a 1D 
NOESY sequence with presaturation on a 
Bruker Avance spectrometer operating at 
500.13 MHz for proton and equipped with a TCI 
entire range of the spectra and the δ scale was 
calibrated to 0 ppm using the internal standard 
TMSP. For statist ical analysis, optimized 1H- 
NMR spectra were automatically baseline cor-
rected and reduced to ASCII files using AMIX 
software (version 3.9; Bruker). The spectral 
intensities were normalized to the creatinine 
signal at 3.05 ppm and reduced to integrated 
regions of equal width (0.04 ppm) corre-
sponding to the 0.5-10.00 ppm region. Beca- 
use of the residual water signal, the region 
between 4.5 and 5.5 ppm was removed before 
further analysis. The matrices obtained were 
used for the statistical analysis. The output 
data were then submitted to a “principal com-
ponent analysis” (PCA) using AMIX software.
Cohort of patients
All KTR from 2007 to 2012 at University of 
Liège Hospital (ULg CHU) were prospectively 
included in a database. Patients actively treat-
ed with cinacalcet on the day of KTx were retro-
spectively identified from this database and 
matched 1:2 with controls on (i) type of donor 
(living (LD), deceased after brain or circulatory 
death (DCD)); (ii) cold ischemic time (CIT) ± 1 
hour; (iii) residual diuresis (± 500 mL); and (iv) 
donor age (± 5 years). Delayed graft function 
(DGF) was defined as the need for RRT in the 
first postoperative week post KTx. Baseline 
characteristics of both groups are summarized 
in Table 3.
Results 
Administration of CaSR agonist, R-568, is not 
nephrotoxic in mouse
Male 10-week-old C57BL/6 mice were daily 
administered with CaSR agonist, R-568, or with 
Table 1. Biological parameters before and after renal ischemia/re-
perfusion in DMSO- and R-568-treated mice
Creatinine (mg/dl) BUN (g/L) Ca2+ (mmol/L)
Before I/R
    DMSO-treated mice 1.02 ± 0.08 0.63 ± 0.09 2.66 ± 0.21
    R-568-treated mice 1.13 ± 0.28 0.81 ± 0.16 2.37 ± 0.27
p (unpaired Student t-test) ns ns p<0.05
Following I/R
    DMSO-treated mice 0.73 ± 0.13 0.78 ± 0.21
    R-568-treated mice 5.74 ± 1.13 4.54 ± 0.82
p (unpaired Student t-test) p<0.05 p<0.05
I/R, ischemia/reperfusion; BUN, blood urea nitrogen; ns, not significant n=8 mice in 
each group.
cryoprobe at 298 K. The 
Noesypresat experiment us- 
ed a RD-90°-T1-90°-Tm-90°-
acquire sequence with a 
relaxation delay of 4 s, a mix-
ing time (Tm) of 10 ms and a 
fixed T1 delay of 4 µs. Water 
suppression pulse was placed 
during the relaxation delay 
(RD). The number of transient 
is 128 (64K data points) and 
a number of 4 dummy scans 
is chosen. Acquisition time is 
fixed to 3.2769001 s. Phase 
and baseline corrections were 
performed manually over the 
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Figure 1. 1H nuclear magnetic resonance (1H-NMR) metabolomics analysis on urine samples from DMSO-treated 
and R-568-treated mice. A. Representative score plot of principal component analysis (PCA, AMIX software) of 
urinary metabolomes of DMSO-treated (red dots) and R-568-treated (blue dots) mice. No significant difference is 
observed between urine metabolite profiles of both groups. B. Representative 1H-NMR spectrum of urine metabo-
lome of a DMSO-treated (upper panel) and an R-568-treated (lower panel) mice. The relative abundance of urinary 
acetoacetate, alanine, 3-hydroxybutyrate and valine, is similar in samples from either group. 
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an equivalent volume of dimethyl-sulfoxide 
(DMSO) by intraperitoneal (i.p.) injections for 48 
hours. Urine was collected in metabolic cages 
for the last 24 hours, whereas blood and kidney 
samples were obtained after anesthesia and 
laparotomy. As previously described [23], 
R-568 administration was associated with a 
significant decrease of serum Ca2+ levels in 
comparison to DMSO treatment (Table 1). 
Conversely, no significant difference in serum 
creatinine and urea levels was observed 
between R-568-treated versus non-treated ani-
mals (Table 1). In order to further assess renal 
safety of R-568 administration in mouse, we 
performed 1H nuclear magnetic resonance (1H-
NMR) metabolomics analysis on urine from 
R-568-treated and control mice. 1H-NMR pro-
files were undistinguishable between groups 
(Figure 1A). Furthermore, the relative abun-
dance of urinary metabolites previously associ-
ated with proximal tubule (PT) toxicity [27], 
including glucose, acetoacetate, alanine, 3-hy- 
droxybutyrate and valine, was similar in sam-
ples from either group (Figure 1B). Finally, com-
parative histological examination of kidneys 
from R-568-treated and DMSO-treated mice 
was undistinguishable in terms of glomerular or 
tubular injury, cell proliferation and apoptosis 
(Table 2). Altogether, these functional and 
structural data support that i.p. administration 
of R-568 in mice does not cause significant 
nephrotoxicity per se. 
Administration of CaSR agonist, R-568, before 
renal I/R exacerbates acute kidney injury in 
mice
Male 10-week-old C57BL/6 mice were daily 
administered with CaSR agonist, R-568, or with 
DMSO by i.p. injections for 48 hours before sur-
Histological examination of kidneys from 
DMSO-pretreated mice revealed acute tubular 
necrosis (ATN), with tubulorrhexis of epithelial 
cells and cylinders of cellular debris in renal 
tubules located in the cortex and at the cortico-
medullary junction (Figure 2). Jablonski’s score 
of ATN severity reached 1 ± 1 in DMSO-treated 
animals (Table 2). Furthermore, numeric quan-
tification of cells positive for proliferative cell 
nuclear antigen (PCNA) and terminal deoxynu-
cleotidyl transferase nick end labeling (TUNEL) 
in kidneys from DMSO-treated mice showed a 
higher rate of cell proliferation and apoptosis 
after I/R in comparison to baseline conditions 
(Table 2). In animals treated by CaSR agonist, 
R-568, before renal I/R, Jablonski’s score of 
ATN severity was significantly higher (3 ± 1, 
p<0.05) in comparison to control group (Figure 
2 and Table 2). Moreover, the number of prolif-
erating cells and apoptotic cells was significant-
ly increased in the cortex and at the cortico-
medullary junction of R-568-treated versus 
DMSO-treated kidneys (Figure 2 and Table 2). 
These observations, including functional and 
histological parameters, suggest that i.p. 
administration of CaSR agonist, R-568, before 
renal I/R worsens the extent of ATN in mouse. 
Treatment with CaSR agonist, cinacalcet, at 
the time of kidney transplantation is associ-
ated with delayed graft function
At the time of KTx, I/R is an unavoidable event, 
which has been associated with delayed graft 
recovery [28]. By definition, delayed graft func-
tion (DGF) corresponds to the need for renal 
replacement therapy (RRT) in the first postop-
erative week [22]. Cinacalcet is an analog of 
R-568 compound, with an improved bioavail-
ability and metabolic profile [29]. Since cinacal-
Table 2. Histological parameters before and after renal ischemia/reper-







cortex c-m junction cortex c-m junction
Before I/R
    DMSO-treated mice 0 16 ± 6 5 ± 3 2 ± 1 2 ± 1
    R-568-treated mice 0 13 ± 6 7 ± 4 3 ± 2 3 ± 2
unpaired Student t-test ns ns ns ns ns
Following I/R
    DMSO-treated mice 1 ± 1 66 ± 12 23 ± 10 8 ± 3 14 ± 8
    R-568-treated mice 3 ± 1 117 ± 31 78 ± 33 12 ± 5 76 ± 19
unpaired Student t-test p<0.05 p<0.05 p<0.05 p<0.05 p<0.05
gical clamping of bilater-
al renal pedicles for 30 
minutes. After unclamp-
ing, mice were kept alive 
for 48 hours with ad libi-
tum access to food and 
drinking water. Analysis 
of serum samples ob- 
tained by vena cava 
puncture at the time of 
sacrifice showed a sig-
nificantly worse AKI in 
R-568-treated mice than 
in controls, as reflected 
by serum creatinine and 
urea levels (Table 1). 
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cet is used in CKD patients with secondary 
hyperparathyroidism [7], individuals registered 
on KTx waiting list are prone to be actively treat-
ed by cinacalcet at the time of KTx. Such a par-
ticular clinical setting provides a unique trans-
lational situation of CaSR activation before 
renal I/R. In our prospective 6-year database of 
337 KTR, we retrospectively identified 36 
(10.7%) patients who were treated by cinacal-
cet at the time of KTx. These patients were 
matched 1:2 to controls according to well-
established factors of DGF, i.e. (i) type of donor, 
(ii) cold ischemic time (CIT), (iii) residual diure-
sis, and (iv) donor age. Control group included 
61 patients. Characteristics of patients and 
donors were compared between groups using 
Student’s t-test or Chi-2 as appropriate, as 
summarized in Table 3. The occurrence of DGF 
was significantly superior in cinacalcet-treated 
patients than in controls (42% versus 23%, 
p=0.05). These retrospective observations in a 
single-centre cohort of KTR suggest that CaSR 
Figure 2. Histological examination of kidneys from DMSO-pretreated and R-568-pretreated mice following ischemia/
reperfusion. Representative kidney sections following I/R injury in mice pretreated with DMSO (A, C, E) or R-568 (B, 
D, F). Periodic acid-Shiff coloration (A, B), immunostaining against Proliferative Cell Nuclear Antigen (PCNA) (C, D), 
or terminal deoxynucleotidyl transferase nick end labeling (TUNEL, ApopTag®) (E, F) were performed. Pictures are 
taken at the cortico-medullary junctions. Arrowheads in panels (A, B) indicate tubulorrhexis-associated intratubular 
debris. Scale bar represents 200 µm and 50 µm in panels (A-F) and insets, respectively.
Impact of CaSR activation before renal I/R
134 Am J Transl Res 2015;7(1):128-138
activation at the time of KTx is more often asso-
ciated with a need for RRT in the first postop-
erative week.
Discussion 
Kidney I/R is the leading cause of AKI, which 
accounts for up to 20% of admissions to 
intensive care units [30]. Furthermore, I/R 
cascade at the time of KTx is responsible for 
early graft dysfunction and enhanced graft 
immunogenicity, which impairs both short- and 
long-term graft survival [28]. Treatment of AKI 
remains largely supportive, including fluid main-
tenance, vasoactive drugs, cytoprotective ther-
apy and extrarenal epuration [30]. Therefore, 
advances in deciphering the pathophysiology of 
renal I/R injury are urgently required to develop 
both preventive and curative approaches of AKI 
[19, 31]. In our mouse model of renal I/R, we 
observed that administration of the CaSR ago-
nist, R-568, before I/R was associated with a 
significantly worsened AKI, at both functional 
and architectural levels. Furthermore, the num-
ber of apoptotic cells in kidney parenchyma 
was significantly greater in R-568-treated ani-
mals in comparison to controls. As previously 
described, apoptosis particularly occurred in 
S3 PT segments, which are located at the corti-
co-medullary junction and are highly vulnerable 
to ischemia [32, 33]. These findings concur 
with recent observations in various ex vivo and 
in vivo models of I/R [15-18]. In cardiomyo-
cytes, the CaSR is involved in I/R-induced 
apoptosis through the mitochondrial pathway 
[16]. Exposure to the CaSR agonist, GdCl3, 
before I/R causes a significant increase in 
phosphorylated protein kinase C δ (PKCδ) 
translocation to the mitochondria, with en- 
hanced release of cytochrome c (Cyt-c) and 
marked reduction of mitochondrial potential. 
Similarly, incubation of Buffalo rat liver cells 
with GdCl3 at the time of simulated I/R further 
induced CaSR expression, increased [Ca2+]i, 
and favored apoptosis through both mitochon-
drial and mitogen-activated protein kinase 
pathways [18]. In vivo, forebrain I/R by tran-
sient bilateral occlusion of carotid arteries in 
C57/BL6 mice increases CaSR expression and 
promotes cell death [17]. Altogether, these 
observations in distinct experimental models 
of I/R suggest a deleterious role of the CaSR in 
I/R-associated cellular cascades. 
The CaSR has been ubiquitously identified [3, 
4]. In the kidney, its distribution remains debat-
ed [34]. In rats, CaSR mRNA is detected along 
essentially the entire nephron, including glom-
eruli, S1-S2 convoluted and S3 straight PT, 
thick ascending limbs of Henlé’s loop (TAL), dis-
tal convoluted tubules (DCT), and collecting 
ducts (CD) [35]. Similarly, immunohistochemis-
try using CaSR-specific antisera documented 
the localization of the CaSR protein in PT, TAL, 
DCT and CD, with a variable polarity upon renal 
cell types [36]. Still, contradictory experimenta-
tions in rats, mice and humans only found the 
CaSR in the TAL [37, 38]. In mice, the i.p. admin-
istration of the CaSR agonist, R-568, induces 
hypocalcaemia [23], as we did observe in our 
Table 3. Clinical features of cinacalcet-treated and control patients at the time of kidney transplanta-
tion
Cinacalcet (n=36) Controls (n=61) p
Recipient Age at Tx (years) 50.2 ± 10.3 49 ± 13.5 0.92
Sex ratio (% female) 47 41 0.55
Dialysis vintage (years) 3.7 ± 2.1 3.3 ± 3.8 0.57
Resting diuresis (ml) 430 ± 655 444 ± 541 0.91
Multi-organ Tx (%) 5.6 1.7 0.28
Donor Age (years) 46.8 ± 11.4 47 ± 11.4 0.93
Sex ratio (% female) 42 46 0.67
LD (%) 2.8 1.6 0.70
DCD (%) 30.6 21.3 0.31
Transplantation CIT (min) 779 ± 297 825 ± 255 0.43
HLA mismatches A 0.8 ± 0.5 0.9 ± 0.5 0.75
B 1.2 ± 0.7 1 ± 0.5 0.08
DR 0.8 ± 0.4 0.8 ± 0.3 0.99
Tx, transplantation; LD, living donor; DCD, donation after cardiac death; CIT, cold ischemic time; HLA, human leukocyte anti-
gen.
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studies. By contrast, the compound R-568 did 
not cause significant nephrotoxicity, as evi-
denced by biological and histological assess-
ment of renal function and by 1H-NMR metabo-
lomics analysis. 1H-NMR is currently used to 
assess drug-induced kidney toxicity [27]. More 
specifically, our findings using 1H-NMR metabo-
lomics show that R-568 administration in 
mouse does not significantly modify the urinary 
metabolome previously linked to S3 PT toxicity. 
In humans, no deleterious impact on kidney 
function has been reported thus far after cina-
calcet treatment (www.amgen.com). In KTR, 
Spanish multicenter observational retrospec-
tive studies reported that cinacalcet therapy 
initiated 20 months after KTx induced a signifi-
cant and sustained decrease of both serum 
Ca2+ and PTH levels, but did not affect renal 
function during a 3-year follow-up [39]. 
Therefore, CaSR activation by the compound 
R-568 should not be regarded as nephrotoxic 
per se, but might make renal tubular cells more 
prone to apoptosis in case of I/R injury. The 
mechanism by which CaSR activation at the 
time of renal I/R enhances AKI severity is 
unknown. It might involve either a direct impact 
on tubular cells, with a rise of [Ca2+]i and stimu-
lation of mitochondria-related apoptotic path-
ways, and/or an indirect effect on the blood 
perfusion of kidney parenchyma. Indeed, intra-
venous infusion of the calcimimetic, R-568, 
induces hypotensive effects in both normoten-
sive and spontaneously hypertensive rats [40, 
41]. The cause of blood pressure drop following 
R-568 administration remains debated, with in 
vitro arguments for both CaSR-dependent and 
CaSR-independent production of nitric oxide 
(NO) [42]. 
KTx currently represents the best treatment for 
end-stage renal disease. Data from the Euro- 
Transplant Network (www.eurotransplant.org) 
show graft survival rates for primary kidney 
transplants of 84%, 78%, and 68% after 1, 3, 
and 5 years, respectively. Acute vascular rejec-
tion and chronic allograft nephropathy remain 
the most relevant risk factors for renal graft 
dysfunction [43]. In addition to immunogenicity, 
organ preservation and I/R participate to kid-
ney injury. DGF is a form of ATN resulting in 
post-transplantation oliguria, increased allo- 
graft immunogenicity and risk of acute rejec-
tion episodes, and decreased long-term surviv-
al. Factors related to the donor and prerenal, 
renal, or postrenal transplant factors related to 
the recipient can contribute to this condition 
[44]. The reported frequency of DGF greatly var-
ies worldwide, from 2% to 50%, upon the ambi-
guity in its definition [22]. Preclinical and clini-
cal studies have particularly demonstrated that 
both ischaemia and reinstitution of blood flow 
in ischemically damaged kidneys after hypo-
thermic preservation play a pivotal part in the 
development of DGF [28]. Therefore, efforts to 
limit I/R injury may help minimize its deleteri-
ous impact on early graft recovery. Our retro-
spective analysis of a single-centre cohort of 
KTR suggests that cinacalcet treatment at the 
time of KTx is more often associated with a 
need for RRT in the first postoperative week. 
Cinacalet is an agonist of the CaSR, which is 
routinely prescribed to treat secondary hyper-
parathyroidism in CKD patients [7]. Mineral 
and bone disorders (MBD) are thought to play a 
part in extraskeletal calcification and dimin-
ished vascular compliance observed in CKD 
patients, thereby contributing to their increased 
cardiovascular risk [45]. Cinacalcet treatment 
may attenuate the progression of vascular and 
cardiac-valve calcification in hemodialysis pa- 
tients, although its beneficial impact on the risk 
of death or major cardiovascular events re- 
mains unproven [46, 47]. 
Our present translational study has several lim-
itations. Our mouse model is restricted to bilat-
eral clamping of renal vascular pedicles, with-
out actual KTx, which does not allow us to take 
into account immune donor/recipient interac-
tions. In addition, mice were only administered 
with the CaSR agonist, R-568, for 48 h before 
I/R, whereas KTR had been chronically treated 
with cinacalcet before KTx. Finally, the retro-
spective pattern of the analysis of our single-
center cohort limits its interpretation. Selection 
bias was reduced by matching 1:2 cinacalcet-
treated and control individuals according to 
well-established factors of DGF. As a whole, our 
data suggest that CaSR activation at the time 
of renal I/R exacerbates AKI. The regulation of 
CaSR activity might thus serve as a novel phar-
macological target to prevent and treat such a 
common condition.
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Supplementary Figure 1. Hybrid human-computer approach to count immunoreactive cells on kidney slides using 
the Cytomine software. A. Immunostaining is performed using antibodies directed against Proliferative Cell Nuclear 
Antigen (PCNA). Whole kidney sections are scanned using the NanoZoomer 2.0 HT (Hamamatsu®). B. Examples 
of PCNA-positive cells are manually encircled. C. Regions of interests, i.e. cortex (red zone) and cortico-medullary 
junction (purple zone), are manually delineated. Then a tree-based machine learning algorithm is used to build a 
positive pixel segmentation model further combined with connected-component analysis and filtering operations 
based on size and circularity criteria.
